# TRUTAKNA (atacicept) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/atacicept

> The FDA approved TRUTAKNA (atacicept), sponsored by Vera Therapeutics, Inc. (VERA), on Jul 2026 for primary IgAN.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TRUTAKNA (atacicept) |
| Codes | VT-001 |
| Sponsor | Vera Therapeutics, Inc. (VERA) https://sec-api.dev/companies/vera/catalysts |
| Indications | [primary igan](https://sec-api.dev/indications/primary-igan), with igan, [IgA Nephropathy](https://sec-api.dev/indications/iga-nephropathy), pMN, [IgA Nephropathy (IgAN)](https://sec-api.dev/indications/iga-nephropathy-igan) |
| Modality | fusion_protein |
| FDA designations | accelerated, breakthrough, orphan, priority review |

## Timeline

### Jan 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-08-05, last confirmed 2026-02-26.
- SEC Form 10-K (accession 0001193125-26-077442): "We reported positive topline 24-week results in January 2023, 36-week results in June 2023, and 96-week results in October 2024 from the ORIGIN 2b trial." https://www.sec.gov/Archives/edgar/data/1831828/000119312526077442/vera-20251231.htm
- SEC prospectus (424B) (accession 0001193125-25-314244): "The Phase 2b ORIGIN clinical trial evaluating the safety and efficacy of atacicept in 116 participants with IgAN reported positive results at three timepoints: 24-week topline results in January 2023, 36-week results in June 2023, 72-week results in January 2024, and 96-week results in October 2024." https://www.sec.gov/Archives/edgar/data/1831828/000119312525314244/d79646d424b5.htm
- SEC prospectus (424B) (accession 0001193125-25-311219): "The Phase 2b ORIGIN clinical trial evaluating the safety and efficacy of atacicept in 116 participants with IgAN reported positive results at three timepoints: 24-week topline results in January 2023, 36-week results in June 2023, 72-week results in January 2024, and 96-week results in October 2024." https://www.sec.gov/Archives/edgar/data/1831828/000119312525311219/d79646d424b5.htm
- SEC prospectus (424B) (accession 0001193125-25-173588): "The Phase 2b ORIGIN clinical trial evaluating the safety and efficacy of atacicept in 116 participants with IgAN reported positive results at three timepoints: 24-week topline results in January 2023, 36-week results in June 2023, 72-week results in January 2024, and 96-week results in October 2024." https://www.sec.gov/Archives/edgar/data/1831828/000119312525173588/d905096d424b5.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-02-28, last confirmed 2025-02-28.
- SEC Form 10-K (accession 0000950170-25-029969): "With Phase 3 topline results expected in the second quarter of 2025, if positive, we expect to submit a biologics license application (BLA) for atacicept in IgAN to the FDA in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1831828/000095017025029969/vera-20241231.htm

### May 15, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: IgA Nephropathy; Berger Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04716231 (Atacicept in Subjects With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.; Results First Posted 2026-10-01." https://clinicaltrials.gov/study/NCT04716231

### Aug 2025: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2026-02-26, last confirmed 2026-02-26.
- SEC Form 10-K (accession 0001193125-26-077442): "Due to the positive results of the ORIGIN program, in August 2025 we initiated the PIONEER trial, a global, open label, Phase 2 basket trial evaluating the safety and initial signals of efficacy of atacicept in an expanded cohort of IgAN patients and other autoimmune-mediated glomerular diseases." https://www.sec.gov/Archives/edgar/data/1831828/000119312526077442/vera-20251231.htm

### Q4 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-02-26, last confirmed 2025-08-05.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-102399): "On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026" https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/vera-ex99_1.htm
- SEC Form 8-K (accession 0001193125-25-132736): "The Company currently plans to submit a biologics license application ("BLA") for accelerated approval for atacicept in IgAN to the FDA in the fourth quarter of 2025, with a projected commercial launch, if approved, in 2026." https://www.sec.gov/Archives/edgar/data/1831828/000119312525132736/d916346d8k.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063975): "Plan to submit a Biologics License Application (BLA) for atacicept in IgAN to the U.S. FDA in 4Q 2025 for accelerated approval; potential PDUFA date and commercial launch in 2026" https://www.sec.gov/Archives/edgar/data/1831828/000095017025063975/vera-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-027337): "On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval planned in 2H 2025" https://www.sec.gov/Archives/edgar/data/1831828/000095017025027337/vera-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-027337): "Plan to submit a BLA to the U.S. FDA in 2H 2025 for atacicept in IgAN for accelerated approval assuming supportive data; and would expect a PDUFA date and commercial launch in 2026" https://www.sec.gov/Archives/edgar/data/1831828/000095017025027337/vera-ex99_1.htm
- SEC Form 10-K (accession 0000950170-25-029969): "With Phase 3 topline results expected in the second quarter of 2025, if positive, we expect to submit a biologics license application (BLA) for atacicept in IgAN to the FDA in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1831828/000095017025029969/vera-20241231.htm
- SEC Form 10-K (accession 0000950170-25-029969): "If positive, we expect to submit a biologics license application (BLA) for atacicept in IgAN to the FDA in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1831828/000095017025029969/vera-20241231.htm
- SEC Form 10-K (accession 0000950170-25-029969): "The Phase 3 primary endpoint results are expected in the first half of 2025, and, if supportive, we expect to submit a BLA to the FDA for accelerated approval of atacicept in IgAN in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1831828/000095017025029969/vera-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-102399): "We anticipate submitting the BLA in the fourth quarter of 2025, with an expected commercial launch in 2026," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics." https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/vera-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-132736): "Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application (BLA) for accelerated approval to the FDA in 4Q 2025; ORIGIN 3 trial continues with two-year results expected in 2027" https://www.sec.gov/Archives/edgar/data/1831828/000119312525132736/d916346dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-132736): "We currently plan to submit a BLA for atacicept in IgAN to the FDA in the fourth quarter of this year, which may allow for US approval and commercial launch in 2026." https://www.sec.gov/Archives/edgar/data/1831828/000119312525132736/d916346dex991.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063975): ""We are rapidly approaching a significant Vera milestone with the upcoming primary endpoint results from the pivotal atacicept ORIGIN 3 trial, and if successful, we expect this to enable a BLA submission to the FDA in the second half of this year, which may allow approval and commercial launch in 2026." https://www.sec.gov/Archives/edgar/data/1831828/000095017025063975/vera-ex99_1.htm

### Nov 2025: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: with IgAN.
- First seen 2026-02-26, last confirmed 2026-05-07.
- SEC Form 10-Q (accession 0001193125-26-212143): "In November 2025, we submitted a Biologics License Application (BLA) for atacicept for the treatment of adults with IgAN to the U.S. Food and Drug Administration (FDA) through the Accelerated Approval Program." https://www.sec.gov/Archives/edgar/data/1831828/000119312526212143/vera-20260331.htm
- SEC Form 10-K (accession 0001193125-26-077442): "In November 2025, we submitted a Biologics License Application (BLA) for atacicept for the treatment of adults with IgAN to the U.S. Food and Drug Administration (FDA) through the Accelerated Approval Program." https://www.sec.gov/Archives/edgar/data/1831828/000119312526077442/vera-20251231.htm

### Jan 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-05-07, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-449826): "In January 2026, the Company achieved a specified regulatory milestone and paid $15.0 million to Ares upon acceptance of the Company's Biologics License Application (BLA) for TRUTAKNA for treatment of IgAN by the FDA." https://www.sec.gov/Archives/edgar/data/1831828/000119312526449826/vera-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342380): "In January 2026, the Company achieved a specified regulatory milestone and paid $15.0 million to Ares upon acceptance of the Company's Biologics License Application for treatment of IgAN by the FDA." https://www.sec.gov/Archives/edgar/data/1831828/000119312526342380/vera-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-212143): "In January 2026, the Company achieved a specified regulatory milestone and paid $15.0 million to Ares upon acceptance of the Company's Biologics License Application for treatment of IgAN by the U.S. Food and Drug Administration." https://www.sec.gov/Archives/edgar/data/1831828/000119312526212143/vera-20260331.htm

### Jul 2026: FDA approval

- Status: completed, approved. Date confidence: month. Indication: primary IgAN.
- First seen 2026-11-05, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-449826): "TRUTAKNA, our first approved product, received accelerated approval from the FDA in July 2026 to reduce proteinuria in adults with primary IgAN who are at risk for disease progression." https://www.sec.gov/Archives/edgar/data/1831828/000119312526449826/vera-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-449826): "Even though TRUTAKNA received accelerated approval from the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression in July 2026, we expect that it will be years, if ever, before revenue from product sales will result in net income." https://www.sec.gov/Archives/edgar/data/1831828/000119312526449826/vera-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-449826): "For example, data from our ORIGIN 3 trial underwent additional analysis after TRUTAKNA received accelerated approval from the FDA in July 2026." https://www.sec.gov/Archives/edgar/data/1831828/000119312526449826/vera-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-449826): "In July 2026, TRUTAKNA received accelerated approval to reduce proteinuria in adults with primary IgAN at risk of disease progression from the FDA and we may attempt to secure accelerated approval for other product candidates in the future." https://www.sec.gov/Archives/edgar/data/1831828/000119312526449826/vera-20260930.htm

### July 7, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 3.
- First seen 2025-02-26, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210351): "FDA granted Priority Review to the atacicept BLA for the treatment of IgAN in adults, and assigned a PDUFA target action date of July 7, 2026" https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/vera-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210351): "Potential FDA accelerated approval of atacicept in IgAN with a PDUFA date of July 7, 2026" https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/vera-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073421): "U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026" https://www.sec.gov/Archives/edgar/data/1831828/000119312526073421/vera-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073421): "FDA granted priority review to the atacicept BLA for the treatment of IgAN in adults, and assigned a PDUFA target action date of July 7, 2026; Company plans for a potential commercial launch in mid-2026" https://www.sec.gov/Archives/edgar/data/1831828/000119312526073421/vera-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073421): "Potential FDA approval of atacicept in IgAN - PDUFA date of July 7, 2026" https://www.sec.gov/Archives/edgar/data/1831828/000119312526073421/vera-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-077442): "Our BLA for atacicept in IgAN was granted Priority Review by the FDA, with a PDUFA target action date of July 7, 2026." https://www.sec.gov/Archives/edgar/data/1831828/000119312526077442/vera-20251231.htm
- SEC Form 10-K (accession 0001193125-26-077442): "The FDA granted priority review to the BLA for atacicept in IgAN and assigned a PDUFA target action date of July 7, 2026." https://www.sec.gov/Archives/edgar/data/1831828/000119312526077442/vera-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-027337): "Plan to submit a BLA to the U.S. FDA in 2H 2025 for atacicept in IgAN for accelerated approval assuming supportive data; and would expect a PDUFA date and commercial launch in 2026" https://www.sec.gov/Archives/edgar/data/1831828/000095017025027337/vera-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-212143): "On January 7, 2026, the FDA granted priority review to the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2026." https://www.sec.gov/Archives/edgar/data/1831828/000119312526212143/vera-20260331.htm
- SEC Form 10-K (accession 0001193125-26-077442): "On January 7, 2026, the FDA granted priority review to the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2026." https://www.sec.gov/Archives/edgar/data/1831828/000119312526077442/vera-20251231.htm
- SEC Form 10-K (accession 0001193125-26-077442): "Our pivotal Phase 3 clinical trial, ORIGIN 3, met the primary endpoint in June 2025, leading to a BLA filing with a PDUFA date of July 7, 2026." https://www.sec.gov/Archives/edgar/data/1831828/000119312526077442/vera-20251231.htm
- SEC Form 10-K (accession 0001193125-26-077442): "The FDA granted priority review to the application and assigned a PDUFA target action date of July 7, 2026." https://www.sec.gov/Archives/edgar/data/1831828/000119312526077442/vera-20251231.htm

### September 22, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: IgA Nephropathy (IgAN); Berger Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07020923 (Monthly Dosing of Atacicept in IgAN): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07020923

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: IgA Nephropathy (IgAN); Berger Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07020923 (Monthly Dosing of Atacicept in IgAN): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07020923

### Q4 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-06-02, last confirmed 2026-09-15.
- SEC Form 8-K (accession 0001193125-26-252475): "Pending these results, the Company plans to submit a supplemental Biologics License Application for full approval of atacicept in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/vera-20260602.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-391280): "the plan to submit a supplemental BLA to the FDA in the fourth quarter of 2026 for full approval" https://www.sec.gov/Archives/edgar/data/1831828/000119312526391280/d32300dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-342335): "Anticipated sBLA submission to the FDA expected in Q4 2026" https://www.sec.gov/Archives/edgar/data/1831828/000119312526342335/vera-ex99_1.htm

### October 1, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: IgA Nephropathy; Berger Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04716231 (Atacicept in Subjects With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.; Results First Posted 2026-10-01." https://clinicaltrials.gov/study/NCT04716231?tab=results

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: pMN; IgAN; Nephrotic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06983028 (Atacicept in Multiple Glomerular Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Vera Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06983028

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: pMN; IgAN; Nephrotic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06983028 (Atacicept in Multiple Glomerular Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Vera Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06983028

## Same indication

- [ADX-097](https://sec-api.dev/pdufa/adx-097) (AKBA)
- [Vanrafia® (atrasentan)](https://sec-api.dev/pdufa/atrasentan) (NVS)
- [BHV-1400](https://sec-api.dev/pdufa/bhv-1400) (BHVN)
- [FABHALTA® (iptacopan)](https://sec-api.dev/pdufa/iptacopan) (NVS)
- [JADE-001](https://sec-api.dev/pdufa/jade101) (JBIO)
- [Sefaxersen](https://sec-api.dev/pdufa/sefaxersen) (IONS)
- [FILSPARI (sparsentan)](https://sec-api.dev/pdufa/sparsentan) (TVTX)
- [Zigakibart](https://sec-api.dev/pdufa/zigakibart) (NVS)

Calendar months: [July 2026](https://sec-api.dev/fda-calendar/2026-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/atacicept.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TRUTAKNA (atacicept) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/atacicept

```bibtex
@misc{secapidev_pdufa_atacicept_20261116,
  title        = {TRUTAKNA (atacicept) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/atacicept}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_atacicept_20261116","title":"TRUTAKNA (atacicept) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/atacicept","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
